BACKGROUND: Latently infected resting memory CD4 T cells are thought to be the major reservoir that contributes to rebound viremia after cessation of antiretrovirals (ARVs). Commencing ARVs during primary HIV-1 infection (PHI) may limit the size of the latent pool and lead to improved control of viral replication during structured treatment interruption (STI). METHODS:Individuals with PHI (n = 59) were randomized to receive ARVs with or without hydroxyurea. After STI, a good response was defined as maintenance of HIV-1 RNA <5000 copies/mL for 24 weeks off therapy. In a detailed prospective virologic substudy (n = 19), integrated HIV-1 DNA, total HIV-1 DNA, and cell-associated HIV-1 unspliced (US) RNA were quantified using a real-time polymerase chain reaction assay. RESULTS: The plasma HIV-1 RNA 12 weeks after the initiation of ARVs was significantly lower in good responders (n = 7) compared with poor responders (n = 12) (P = 0.005). There were no significant differences between good and poor responders in integrated HIV-1 DNA, HIV-1 DNA, and HIV-1 US RNA. Integrated HIV-1 DNA before initiation of ARVs was strongly correlated with plasma HIV-1 RNA at week 12 (P = 0.006, r = 0.81). CONCLUSION: HIV-1 RNA measured 12 weeks after initiation of ARV was the only virologic variable associated with viral rebound after treatment interruption in PHI.
RCT Entities:
BACKGROUND: Latently infected resting memory CD4 T cells are thought to be the major reservoir that contributes to rebound viremia after cessation of antiretrovirals (ARVs). Commencing ARVs during primary HIV-1 infection (PHI) may limit the size of the latent pool and lead to improved control of viral replication during structured treatment interruption (STI). METHODS: Individuals with PHI (n = 59) were randomized to receive ARVs with or without hydroxyurea. After STI, a good response was defined as maintenance of HIV-1 RNA <5000 copies/mL for 24 weeks off therapy. In a detailed prospective virologic substudy (n = 19), integrated HIV-1 DNA, total HIV-1 DNA, and cell-associated HIV-1 unspliced (US) RNA were quantified using a real-time polymerase chain reaction assay. RESULTS: The plasma HIV-1 RNA 12 weeks after the initiation of ARVs was significantly lower in good responders (n = 7) compared with poor responders (n = 12) (P = 0.005). There were no significant differences between good and poor responders in integrated HIV-1 DNA, HIV-1 DNA, and HIV-1 US RNA. Integrated HIV-1 DNA before initiation of ARVs was strongly correlated with plasma HIV-1 RNA at week 12 (P = 0.006, r = 0.81). CONCLUSION:HIV-1 RNA measured 12 weeks after initiation of ARV was the only virologic variable associated with viral rebound after treatment interruption in PHI.
Authors: Grant R Campbell; Rachel S Bruckman; Yen-Lin Chu; Rodney N Trout; Stephen A Spector Journal: Cell Host Microbe Date: 2018-10-18 Impact factor: 21.023
Authors: Kersten K Koelsch; Thomas A Rasmussen; William J Hey-Nguyen; Chester Pearson; Yin Xu; Michelle Bailey; Katherine H Marks; Sarah C Sasson; Mark S Taylor; Robyn Tantau; Solange Obeid; Brad Milner; Orla Morrissey; Angie N Pinto; Kazuo Suzuki; Michael P Busch; Sheila M Keating; Philipp Kaiser; Steven Yukl; Joseph K Wong; Bonnie M Hiener; Sarah Palmer; John Zaunders; Jeffrey J Post; Derek J Chan; Sharon Avery; Sam T Milliken; Anthony D Kelleher; Sharon R Lewin; David A Cooper Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout Journal: JCI Insight Date: 2020-03-26
Authors: Paul Volberding; Lisa Demeter; Ronald J Bosch; Evgenia Aga; Carla Pettinelli; Martin Hirsch; Mary Vogler; Ana Martinez; Susan Little; Elizabeth Connick Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: Lachlan R Gray; Michael Roche; Jacqueline K Flynn; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill Journal: Curr Opin HIV AIDS Date: 2014-11 Impact factor: 4.283